Wall Street Holds Steady as Investors Await Key Fed Rate Cut Decision
Uncertainty Looms Over the Size of the Easing, With Tech Stocks Poised to Benefit Stocks held relatively flat on Wednesday...
Victoria’s Secret: A Balanced Approach to Recovery with Equal Weight Upgrade
New Leadership and Strategic Shifts Drive Hope Amid Challenges Victoria's Secret & Co. (VSCO) is entering a critical phase in...
BlackRock and Microsoft Join Forces for $100 Billion AI Infrastructure Investment
Global AI Infrastructure Investment Partnership to boost data centers and energy infrastructure for AI expansion BlackRock (BLK) and Microsoft (MSFT)...
Intel Misses Out on PlayStation 6 Chip Deal: A Setback to Its Foundry Ambitions
Failed Contract Highlights Competitive Pressures and Strategic Shifts In a bid to reinvigorate its struggling business, Intel Corporation (INTC) sought...
Eli Lilly to Invest $1.8 Billion in Expanding Manufacturing for Alzheimer’s, Diabetes, and Obesity Treatments in Ireland
Major investments in Limerick and Kinsale will help meet soaring demand for key drugs Eli Lilly (LLY) has announced plans...
Tesla Poised to Reshape Multiple Industries: From Robotaxis to Humanoid Robots
An In-Depth Look at Tesla’s Vision for the Future of Technology Tesla (TSLA), widely known for revolutionizing the electric vehicle...
Cathie Wood’s Ark Invest Makes Bold Moves: Buys DraftKings, AMD, and Tempus AI; Sells Palantir and Unity
Key Investments Highlight Strategic Shifts in Tech and AI Focus Cathie Wood, CEO of Ark Invest and one of Wall...
JPMorgan Chase Shares Plunge as President Warns of Optimistic 2025 Projections
Inflation, Federal Reserve Policies, and Investment Challenges Impact Outlook JPMorgan Chase (JPM), the largest U.S. bank by assets, saw its...
Advancements in EGFR-Targeted Therapies: Promising Phase 1b Data for Firmonertinib in NSCLC Patients with Rare EGFR Mutations
Novel treatments show potential in addressing hard-to-treat mutations in lung cancer, bringing hope for improved outcomes ArriVent Biopharma recently unveiled...
Summit Therapeutics Announces Promising Phase III Trial Results for Ivonescimab in Lung Cancer
First-line treatment shows significant improvement in progression-free survival over pembrolizumab, marking a potential shift in NSCLC care Summit Therapeutics (SMMT)...
